Such a relationship seems warranted, especially in light of the PI*Z disease-modifying role in liver diseases, i.e., in triggering hepatic dysfunction in cystic fibrosis (Bartlett et al., 2009; Elborn, 2016), as a disease modifier in alcoholic (AFLD) and nonalcoholic (NAFLD) fatty liver disease (Abul-Husn et al., 2018; Strnad et al., 2019), or due to its link to higher serum ALT and AST levels (Prins et al., 2017). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.